Apimeds Pharmaceuticals US completes $13.5M IPO; starts trading on NYSE American

Apimeds Pharmaceuticals US, Inc.

IPO of 3,375,000 shares at $4.00/share; gross proceeds $13.5M.
Proceeds to fund Phase III knee osteoarthritis trial, MS study, manufacturing, working capital.
Convertible notes of $772,545 converted into 297,133 shares at $2.60/share.
Underwriters granted 45-day option for 506,250 additional shares and warrants for 168,750 shares.
Trading began May 9, 2025 on NYSE American under symbol APUS.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.